Cost-effectiveness of primary and secondary prevention in cardiovascular diseases

European Heart Journal

Volumn 19, Issue SUPPL C, 1998, Pages

  Troche, C J ^a   Tacke, J ^a   Hinzpeter, B ^a   Danner, R ^a   Lauterbach, K W ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Coronary heart disease; Cost effectiveness analysis; Health economics; HMG CoA reductase inhibitors; Primary and secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; STATIN;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRAVASTATIN; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN;

EID: 0031953071     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)